A Study Evaluating the Safety, Pharmacokinetics, and Activity of the Combination of Cevostamab and Elranatamab in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM)

Who May Qualify: - Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1 - Diagnosis of R/R MM per IMWG criteria - For female participants of childbearing potential: agreement to remain abstinent or use contraception - For male participants: agreement to remain abstinent or use a condom Who Should NOT Join This Trial: - Prior treatment with cevostamab or another agent targeting fragment crystallizable receptor-like 5 (FcRH5) - Prior treatment with elranatamab - Prior allogeneic stem cell transplantation (SCT) - Absolute plasma cell count exceeding 500 per milliliter (mL) or 5% of the peripheral blood white cells - Diagnosis of Waldenström macroglobulinemia or polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, skin changes (POEMS) syndrome - Participants with known history of amyloidosis - History of autoimmune conditions (where your immune system attacks your own body) - History of confirmed progressive multifocal leukoencephalopathy - Peripheral motor polyneuropathy of prespecified grade - Known or suspected chronic cytomegalovirus (CMV) and/or Epstein-Barr virus (EBV) infection - Known history of hemophagocytic lymphohistiocytosis (HLH) or macrophage activation syndrome (MAS) - Acute or chronic hepatitis B virus (HBV) or hepatitis C virus (HCV) infection - Human weakened immune system virus (HIV) seropositivity - History of central nervous system (CNS) myeloma disease - Significant cardiovascular disease Always talk to your doctor about whether this trial is right for you.